Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.

Abstract: Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis.

Abstract: A composition for use in a nasal application, the composition including an aqueous carrier and a viscosity agent. The viscosity agent is in the range of about 4% to about 15% by weight. The viscosity agent is in solution with the aqueous carrier. The solution of the aqueous carrier and the viscosity agent is configured as a thixotropic composition.

Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Abstract: Embodiments herein include coated medical devices and coatings with salt groups. In an embodiment, a coated medical device is included, the coated medical device including a substrate and a polymeric layer disposed over the substrate. The polymeric layer includes a polymer and has an exterior surface. The coated medical device further includes a plurality of salt groups bonded to the polymer of the polymeric layer and disposed on the exterior surface of the polymeric layer. The salt groups can be the reaction product of a reactive group with an acid or base. In an embodiment, a method of making a medical device is included. Other embodiments are also included herein.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.

Abstract: Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 ?m to 2000 ?m and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Abstract: An antimicrobial polymer for use in an ophthalmic implant, includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic, silicone, vinyl and collagen monomer.

Abstract: A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent—works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialization; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).

Abstract: The present invention relates to an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide. An embolization particle of the invention for use in the treatment of cancer in combination with X-ray radiation or proton beam radiation, or use in embolization, is also described. The invention also relates to a process for producing an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide, which process comprises: (i) providing a microparticle; (ii) contacting the microparticle with a plurality of the nanoparticles; and (iii) heating the microparticle and the nanoparticles to form the embolization particle.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: The present invention relates generally to methods of preparing antimicrobial elastomeric articles that include an elastomeric article having an antimicrobial coating provided thereon. The antimicrobial elastomeric articles exhibit enhanced ability to reduce or eliminate microbes that come in contact with the article. Certain aspects of the invention are further directed to methods of packaging the antimicrobial elastomeric articles, where the packaged antimicrobial articles exhibit antimicrobial effectiveness for an extended period of time as compared to unpackaged antimicrobial articles. Antimicrobial elastomeric articles and packaged antimicrobial elastomeric articles prepared in accordance with the methods of the present invention are also provided.

Abstract: TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.

Abstract: Disclosed herein is a block copolymer comprising a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers; and a second block derived from an acrylate monomer. Disclosed herein too is a method comprising reacting a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers with an initiator to form a macroinitiator; and polymerizing a second block onto the first block to form a block copolymer; where the second block is derived by polymerizing an acrylate monomer; and where the block copolymer has a chi parameter of greater than or equal to about 0.05, when measured at a temperature of 200° C. to 210° C.; where the chi parameter is a measure of interactions between the first block and the second block of the copolymer.

Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.

Abstract: Disclosed are: (a) controlled release matrix particles containing 10-70 wt. % of a hydrophobic active ingredient, 21-72 wt. % of a polysaccharide, 3.80-12 wt. % of a crosslinking agent, 1.00-6 wt. % of a catalyst and 0.10-5 wt. % of a silica flow aid; (b) controlled release core/shell particles containing 10-70 wt. % of a hydrophobic active ingredient, 1.0-3.2 wt. % of an epoxidized oil, 21-64 wt. % of a polysaccharide, 7.6-23% of an amine-functionality containing material, and 0.10-5 wt. % of a silica flow aid; and (c) hybrid particles wherein the core/shell particles are contained in a matrix. Also disclosed are methods for making the particles and compositions containing the particles.

Abstract: The present invention relates to biodegradable polyesteramides (PEAs) comprising hydrophobic alpha-amino acids, diols, aliphatic dicarboxylic acids and optionally diamines whereby at least one of the dicarboxylic acids, diols or diamines comprises disulphide linkages. The present invention also relates to the use of the polyesteramides in medical applications such as cancer treatment, ophthalmic applications, therapeutic cardiovascular applications, veterinary applications, pain management applications, MSK applications and vaccine delivery compositions. The present invention also relates to a drug delivery composition comprising the PEA's and to a drug delivery system such as micro- or nanoparticles, micelles, liposomes, polymerosomes, micro- and nanogels, polymerosomes or nanotubes.

Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

Abstract: An object of the present invention is to provide a composition that serves as an efficient arginine substrate for inducible NO synthase (iNOS) in tumor. The present invention provides a polyion complex (PIC) of PEG-b-poly(L-Arg) or poly(L-Arg)-b-PEG-b-poly(L-Arg) and a polyanionic polymer, and use thereof.

Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.

Abstract: Biodegradable, bioabsorbable cross-linked polymer tissue scaffolds for filling a void in human or animal soft tissue, such as a surgical or other wound, are disclosed. Drugs incorporated into the polymer backbone and/or loaded into the matrix are released directly to the target site. Additional non-toxic chemical constituents can be used to tune the hydrophilio hydrophobic and other physical properties of the cross-linked polymer tissue scaffolds, and incorporating brominated or iodinated constituents provides radio-opacity. The radio-opaque cross-linked polymer tissue scaffolds can assist in the targeting of radiation therapy.

Abstract: A water treatment solution may include a metal salt and a base product fluid. The base product fluid may include a molecular compound that is a chelating compound. The molecular compound may have the formula: ((NH4)2SO4)a.(H2SO4)b.(H2O)c.(NH4HSO4)x. In the formula, a may be between 1 and 5, b may be between 1 and 5, c may be between 1 and 5, and x may be between 1 and 10. The water treatment solution may be formed by adding the metal salt to the base product fluid and water. The water treatment solution may be added to water in need of treatment. The water in need of treatment may be a static body of water.

Abstract: A polymer-micelle complex suitable for use as an aid to preparing fibers, particularly nanofibers, by electrospinning. The polymer-micelle complex may be designed to impart viscosity, surface tension and conductivity properties optimal for electrospinning. By incorporating the complex as a secondary ingredient, one may electrospin sparingly soluble or low molecular weight polymers. Moreover, the polymer-micelle complex can be used as a generic carrier for preparing fibers incorporating other desired materials, such as rigid or globular (hard-to-spin) polymers, enzymes, cells, viral particles and nanoparticles.

Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.

Abstract: Disclosed is a composition for forming an injectable hydrogel. The composition includes 1% by weight or less of a graphene-based material and 5% by weight or more of a triblock copolymer. The triblock copolymer may be a copolymer represented by Formula 1: wherein n is an integer from 8 to 540, m is an integer from 16 to 70, and R is H or a vinylcarbonyl group (CH2?CHCO—). When R in Formula 1 is a vinylcarbonyl group, the triblock copolymer may be crosslinked through the vinylcarbonyl group to form a nanogel. The composition can be prepared by a simple mixing process. In addition, the composition is substantially free from in vitro and in vivo stability problems encountered with conventional hydrogel compositions. Furthermore, the composition has high biocompatibility as well as excellent mechanical properties such as high storage modulus.

Abstract: The dermatological compositions deliver water and/or other hydrophilic compounds into or through the dermis using reverse micelles. The compositions include an oil-based continuous phase and an emulsifier that form nanoparticle micelles. The nanoparticle micelles are formulated into biocompatible topical ointments that are stable at room temperature and can be distributed in consumer packaging and consumer distribution channels.

Abstract: A molding compact for forming a transdermal absorption sheet on which a needle-shaped protruding part is arranged is a molding compact that is a laminate of: a first member having a needle-shaped recessed part formed on a front surface thereof, the needle-shaped recessed part being an inverse of the needle-shaped protruding part; a second member provided on a back surface of the first member, the second member being composed of a waterproof and moisture-permeable material; and a third member provided on a back surface of the second member, the third member being composed of a rigid body. Provided are a molding compact that makes it possible to prevent leakage of a drug-containing solution filled into the needle-shaped recessed part, and a manufacturing method for a transdermal absorption sheet using the molding compact.

Abstract: The present invention provides compositions and methods for the treatment of cancer are provided.

Abstract: The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include temporary ALDH2 deficiency, such as that seen by alcohol poisoning or an ischemic event.

Abstract: Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.

Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.

Abstract: The present invention provides dental bonding agents and dental bonding systems comprising the dental bonding agents. The dental bonding agents of the invention are characterized by having antibacterial properties, and in some aspects of the invention, remineralizing properties.

Abstract: A skin defense system and a skin rejuvenation and defense system. The skin rejuvenation and defense system includes a skin rejuvenation application and a skin defense application that work together synergistically to rejuvenate and defend the skin from environmental insults that can accelerate the aging process and deprive the skin of its vitality. The skin rejuvenation application invigorates, oxygenates, and detoxifies the skin. After the skin has been opened up and made receptive by the skin rejuvenation application, the skin defense application absorbs into the skin to deeply moisturize and revitalize the skin. In addition to moisturizers, emollients, and similar ingredients that improve health and appearance of the skin, the skin defense application includes ingredients that can reverse and protect the skin from damage caused by pollutants (e.g., pollutants up to 2.5 micrometers) and pre- and pro-biotics that promote the growth and development of beneficial skin flora.

Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.

Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.

Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, nm) of 100-500 nm, where the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc.

Abstract: Disclosed is a process of preparing sustained release microspheres, containing a biodegradable polymer as a carrier and a drug, using spray drying. The process comprises preparing a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent; spray drying the solution, suspension or emulsion; and suspending spray-dried microspheres in an aqueous solution containing polyvinyl alcohol to remove the residual solvent and increase the hydrophilicity of the microsphere surface. The process enables the preparation of microspheres having high drug encapsulation efficiency, almost not having a toxicity problem due to the residual solvent, and having good syringeability. The microspheres prepared according to the present invention release an effective concentration of a drug in a sustained manner for a predetermined period when administered to the body, and are thus useful in the treatment of diseases.

Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.

Abstract: The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by using an emulsification method, without involving the steps of chemical treatment of the surface of hydrogels or dilution, thereby facilitating mass production and preventing the decrease of drug encapsulation efficiency.

Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.

Abstract: Described herein are abuse deterrent oral pharmaceutical compositions, methods for making the same, and methods of treatment using such compositions. In particular, oral pharmaceutical compositions that mitigate the risk of overingestion of one or more active pharmaceutical ingredients are described.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

Abstract: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.

Abstract: A compound of formula the following formula: (I). In this formula, moieties A, B, X, R1, R2, and R3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.

Abstract: Disclosed is a cosmetic or dermatological preparation which comprises one or more extracts of Saxifraga oppositifolia (purple saxifrage) and/or one or more extracts of Soldanella alpina (alpine snowbell). The use of these extracts to combat extrinsic and intrinsic skin aging is likewise described.

Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.